Skip to main
RNAC
RNAC logo

RNAC Stock Forecast & Price Target

RNAC Analyst Ratings

Based on 1 analyst ratings
Buy
Strong Buy 0%
Buy 100%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Cartesian Therapeutics is positioned for a positive financial outlook due to anticipated favorable data from its Phase 3 trial of Descartes-08, following strong results from Phase 2 trials and widespread market acceptance projected in both the US and EU. The company's innovative ImmTOR platform, which promotes outpatient administration without lymphodepleting chemotherapy, underscores the potential for significant patient engagement and treatment adoption. Furthermore, ongoing developments, including additional trials in systemic lupus erythematosus and pediatric autoimmune diseases slated for late 2025, reflect the company's commitment to expanding its therapeutic pipeline, which may enhance its growth prospects.

Bears say

Cartesian Therapeutics reported a significant net loss of $0.40 per share for the fourth quarter of 2024, raising concerns about its financial sustainability amid operational challenges. The variability in treatment effects and the observed decline in the efficacy of Vyvgart after four weeks necessitate frequent re-treatment, which could hinder patient adoption and long-term revenue generation. Additionally, risks such as delays in clinical trials, unfavorable data from key studies like Descartes-08, and potential long-term dilution pose further threats to the company's financial performance and stock outlook.

RNAC has been analyzed by 1 analysts, with a consensus rating of Buy. 0% of analysts recommend a Strong Buy, 100% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Cartesian Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Cartesian Therapeutics Inc (RNAC) Forecast

Analysts have given RNAC a Buy based on their latest research and market trends.

According to 1 analysts, RNAC has a Buy consensus rating as of Jul 10, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $38, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $38, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Cartesian Therapeutics Inc (RNAC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.